Results 181 to 190 of about 107,831 (252)

Diagnostic and Therapeutic Challenges in Seronegative Autoimmune Hepatitis With Concurrent Graves Disease and Immune Thrombocytopenia. [PDF]

ACG Case Rep J
McLeod B, Walia N, Rao V, Krishnamoorthi B, Lin A, Fuller P, Braude M.   +6 more
europepmc   +1 more source

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

Eosinophilic annular erythema in a patient with hepatitis B-related cirrhosis. [PDF]

An Bras Dermatol
Vilela BF, Fialho MC, Ferreirinha A, Fernandes C.   +3 more
europepmc   +1 more source

Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis

Hepatology Research, EarlyView.
IDO‐1 immunostaining identifies primary biliary cholangitis even in morphologically subtle bile duct lesions. IDO‐1 expression reflects cholangitis activity and is suppressed by ursodeoxycholic acid treatment, indicating its value as a dynamic diagnostic adjunct rather than a static marker of chronic damage.
Kaori Yoshimura, Shinji Shimoda, Ryoka Masuda, Tram Nguyen Thi, Rui Yang, Quynh Nguyen Thi, Dong Le Thanh, Yuko Tamano, Yasunori Sato, Taro Yamashita, Kenichi Harada   +10 more
wiley   +1 more source

Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH). [PDF]

Support Care Cancer
Swaminathan M, Angelakas A, Baxter M, Cotton J, Dobeson C, Feeney L, Gault A, Hughes DJ, Jones C, Lee R, Mughal S, Parikh S, Pritchard DM, Rodgers L, Rowe M, Salawu A, Shotton R, Tinsley N, Tivey A, Zhao S, Olsson-Brown AC.   +20 more
europepmc   +1 more source

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury

Hepatology Research, EarlyView.
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma, Yoshihito Uchida, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Suguru Mizuno, Satoshi Mochida   +7 more
wiley   +1 more source

Progressive Pulmonary Cystic Disease in Autoimmune Hepatitis and Rheumatoid Arthritis: A Rare Association. [PDF]

Cureus
Kantheti HS, Huynh KT, Kanase N, Amar MH, Srinivasan L.   +4 more
europepmc   +1 more source

The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan

International Journal of Dermatology, EarlyView.
ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen, Deema Abdel Hafeez, Nikhil Pai, Laurence Mainville, Shireen Dumont, Narachai Julanon, Romy Shenderey, Grace Xiong, Shahnawaz Towheed, Jeffrey Donovan   +9 more
wiley   +1 more source

Interleukin-17 in Health and Disease: Special Focus on Its Role in Autoimmune Hepatitis. [PDF]

Cells
Agoston Ş, Grama A, Onaciu A, Mititelu A, Benţa G, Pop TL.   +5 more
europepmc   +1 more source

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source